Doxycycline reduces cardiac Matrix Metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass.

Schulze CJ, Castro MM, Kandasamy AD, Cena J, Bryden C, Wang SH, Koshal A, Tsuyuki RT, Finegan BA, Schulz R.
Journal   Crit Care Med.
Analytes Measured   Troponin I cardiac
Matrix Tested   Plasma
Year   2013
Page Numbers  
Application   Toxicology
OBJECTIVES: Matrix metalloproteinase-2 proteolyzes intracellular proteins in the heart and induces acute myocardial contractile dysfunction in ischemia-reperfusion injury. Doxycycline, a matrix metalloproteinase inhibitor, prevented matrix metalloproteinase-2-induced troponin I cleavage in rat hearts and improved contractile function following ischemia-reperfusion. In patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass, increased atrial matrix metalloproteinase-2 activity was inversely correlated with cardiac mechanical function at 3 hours reperfusion. We performed a study in patients with coronary artery disease undergoing primary elective coronary artery bypass graft surgery with cardiopulmonary bypass to determine whether doxycycline reduces cardiac mechanical dysfunction, matrix metalloproteinase activity, and troponin I degradation after reperfusion.

DESIGN: Randomized, double-blinded, placebo-controlled study.

SETTING: University of Alberta Hospital.

PATIENTS: Forty-two patients with coronary artery disease undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.

INTERVENTIONS: Patients were randomized to receive either oral administration of 20 mg of doxycycline or matching placebo pill twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days.

MEASUREMENTS AND MAIN RESULTS: Left ventricular stroke work index was examined prior to cardiopulmonary bypass and at 24 hours reperfusion. Right atrial biopsies were collected before cardiopulmonary bypass and 10 minutes after aortic cross-clamp release to determine matrix metalloproteinase-2 activity and troponin I level. Blood was collected to determine matrix metalloproteinase activity and interleukin-6, C-reactive protein, and troponin I levels. Cardiac 72-kDa matrix metalloproteinase-2 activity was lower upon reperfusion in biopsies from the doxycycline group (p = 0.01), and the increase of matrix metalloproteinase-2 activity in the placebo group due to reperfusion did not appear in the doxycycline group (p = 0.05). Doxycycline, however, did not ameliorate cardiac mechanical dysfunction following reperfusion or the cardiopulmonary bypass-coronary artery bypass graft-induced increased plasma matrix metalloproteinase-9, interleukin-6, and C-reactive protein levels. Cardiopulmonary bypass-coronary artery bypass graft or doxycycline did not change tissue or plasma troponin I levels at 10 minutes reperfusion.

CONCLUSIONS: Although doxycycline did not improve myocardial stunning following coronary artery bypass graft surgery with cardiopulmonary bypass, it reduced cardiac matrix metalloproteinase-2 activity in these patients. A larger trial and/or higher dose of doxycycline may yet be warranted.

View Publications

Related Products

Muscle Injury Panel 3 Mouse Kit
cTroponin I, FABP3/H-FABP, Myl3/CMLC1, Troponin I (fast-twitch) | Mouse
Muscle Injury Panel 1 Rat Kit
cTroponin I, FABP3/H-FABP, Myl3/CMLC1, Troponin I (fast-twitch), Troponin T (cardiac) | Rat
Rat Cardiac Troponin ITC Complex Kit
cTroponin I, Troponin ITC Complex | Rat
Cardiac Injury Panel 2 Rat Kit
cTroponin I, FABP3/H-FABP, Troponin T (cardiac) | Rat
Cardiac Injury Panel 3 Rat Kit
cTroponin I, FABP3/H-FABP, Myl3/CMLC1, Troponin T (cardiac) | Rat
Browse Our Products

By Analytes
By Applications
Customer Service/Orders

Scientific/Technical Support

Instrument Support

Company Headquarters